Transgene Biotek Limited (TRABI.BO)
INR 7.34
(-0.53%)
INR 7.34
(-0.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.55 Million INR | 89.09% |
| 2022 | -60.08 Million INR | 42.24% |
| 2021 | -104.02 Million INR | 0.31% |
| 2020 | -104.34 Million INR | 4.81% |
| 2019 | -109.62 Million INR | -24.67% |
| 2018 | -87.92 Million INR | -36.56% |
| 2017 | -64.38 Million INR | 67.58% |
| 2016 | -198.6 Million INR | 7.79% |
| 2015 | -215.38 Million INR | -12.56% |
| 2014 | -191.35 Million INR | 85.66% |
| 2013 | -1.33 Billion INR | -6457.84% |
| 2012 | -20.34 Million INR | -117.54% |
| 2011 | 115.96 Million INR | 8378.09% |
| 2010 | 1.36 Million INR | -64.15% |
| 2009 | 3.81 Million INR | 1.13% |
| 2008 | 3.77 Million INR | -59.57% |
| 2007 | 9.33 Million INR | -24.73% |
| 2006 | 12.39 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.99 Million INR | 173.23% |
| 2023 FY | -6.55 Million INR | 89.09% |
| 2023 Q2 | -1.32 Million INR | 4.53% |
| 2023 Q1 | -1.38 Million INR | 90.56% |
| 2023 Q4 | -2.72 Million INR | -128.63% |
| 2023 Q3 | -1.19 Million INR | 10.17% |
| 2022 FY | -60.08 Million INR | 42.24% |
| 2022 Q2 | -17.69 Million INR | -27.47% |
| 2022 Q3 | -13.79 Million INR | 22.06% |
| 2022 Q1 | -13.88 Million INR | 45.46% |
| 2022 Q4 | -14.71 Million INR | -6.69% |
| 2021 Q4 | -25.45 Million INR | 3.7% |
| 2021 Q1 | -26.11 Million INR | -0.13% |
| 2021 FY | -104.02 Million INR | 0.31% |
| 2021 Q3 | -26.43 Million INR | -1.53% |
| 2021 Q2 | -26.03 Million INR | 0.3% |
| 2020 FY | -104.34 Million INR | 4.81% |
| 2020 Q1 | -26.36 Million INR | 5.39% |
| 2020 Q2 | -26.73 Million INR | -1.39% |
| 2020 Q3 | -25.16 Million INR | 5.87% |
| 2020 Q4 | -26.07 Million INR | -3.63% |
| 2019 FY | -109.62 Million INR | -24.67% |
| 2019 Q4 | -27.86 Million INR | -4.72% |
| 2019 Q3 | -26.61 Million INR | 2.61% |
| 2019 Q2 | -27.32 Million INR | 1.75% |
| 2019 Q1 | -27.81 Million INR | -2.81% |
| 2018 Q4 | -27.05 Million INR | -192.22% |
| 2018 FY | -87.92 Million INR | -36.56% |
| 2018 Q3 | -9.25 Million INR | 65.38% |
| 2018 Q2 | -26.73 Million INR | -7.46% |
| 2018 Q1 | -24.88 Million INR | 0.0% |
| 2017 FY | -64.38 Million INR | 67.58% |
| 2016 FY | -198.6 Million INR | 7.79% |
| 2016 Q4 | - INR | 0.0% |
| 2015 FY | -215.38 Million INR | -12.56% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | -191.35 Million INR | 85.66% |
| 2013 FY | -1.33 Billion INR | -6457.84% |
| 2012 Q3 | 50.88 Million INR | 136.04% |
| 2012 Q2 | -141.16 Million INR | -208.84% |
| 2012 Q1 | 129.69 Million INR | 0.0% |
| 2012 FY | -20.34 Million INR | -117.54% |
| 2012 Q4 | -105.55 Million INR | -307.45% |
| 2011 FY | 115.96 Million INR | 8378.09% |
| 2010 FY | 1.36 Million INR | -64.15% |
| 2009 FY | 3.81 Million INR | 1.13% |
| 2008 FY | 3.77 Million INR | -59.57% |
| 2007 FY | 9.33 Million INR | -24.73% |
| 2006 FY | 12.39 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 2.76 Million INR | 337.156% |
| Biocon Limited | 10.22 Billion INR | 100.064% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 100.4% |
| Concord Biotech Limited | 3.08 Billion INR | 100.213% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 99.573% |
| FERMENTA BIOTECH LIMITED | -230.59 Million INR | 97.157% |
| GENOMIC VALLEY BIOTECH LIMITED | 151.81 Thousand INR | 4417.67% |
| Lyka Labs Limited | -24.89 Million INR | 73.668% |
| Panacea Biotec Limited | -11.73 Million INR | 44.118% |
| SAMSRITA LABS LIMITED | -2.62 Million INR | -149.957% |
| Servoteach Industries Limited | -2.37 Million INR | -176.116% |
| SMS Lifesciences India Limited | 90.92 Million INR | 107.209% |
| Supriya Lifescience Limited | 1.19 Billion INR | 100.55% |
| Syngene International Limited | 5.1 Billion INR | 100.129% |
| TAKE Solutions Limited | -1.19 Billion INR | 99.452% |
| Titan Biotech Limited | 248.53 Million INR | 102.638% |
| Vanta Bioscience Limited | -23.15 Million INR | 71.696% |